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Introduction
Muscle contracture is defined as ‘the abnormal shorten-
ing of muscle tissue, rendering the muscle highly resist-
ant to stretching’.1 Muscle contracture occurs as a result 
of muscle fibrosis, often the result of injury. In veterinary 
patients, acquired muscle contracture most commonly 
develops secondary to a traumatic event.2 Other causes 
of muscle contracture include, but are not limited to, 
compartment syndrome, infection, immune-mediated 
disease, circulatory insufficiency, eosinophilic myositis 
and myositis ossificans.3 Theoretically, any muscle can 
become affected, but canine and feline muscle contrac-
ture most commonly affects the quadriceps and infra-
spinatus. Less commonly affected muscles include the 
supraspinatus, teres minor, sartorius, gracilis and 
semitendinosus.4 Contracture can cause permanent disability 
and is often associated with pain and lameness. 
Treatment options and prognosis depend on the severity 
of the contracture and the muscle(s) affected. 
Conservative management involving physiotherapy 
and splinting can be effective in mild cases. However, 
severe cases of muscle contracture often require 
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Abstract
Case summary A 4-month-old male entire domestic shorthair cat presented for sudden onset of right thoracic 
monoparesis following a fall; within 18 h, the clinical signs progressed to non-ambulatory right hemiplegia with 
absent sensation in the distal right thoracic limb and left hemiparesis. MRI revealed changes consistent with a 
C6–C7 acute non-compressive nucleus pulposus extrusion with suspected secondary C5–C7 spinal cord haemorrhage. 
Rehabilitation exercises were started immediately after the diagnosis of acute spinal cord trauma. Sensation in the 
right thoracic limb improved and, with the help of a splint applied to that limb, the cat was ambulatory on all four limbs. 
Unfortunately, clinical signs started to progress over the course of 10 days. The cat developed progressive discomfort 
on manipulation of the right elbow and carpus, and a hyperflexion of the right carpus. Radiographs revealed no skeletal 
abnormalities. Muscle contractures were suspected. Under general anaesthesia the triceps and flexor muscles of 
the carpus and digits were injected with a total of 100 U of botulinum toxin type A (BTX-A). No complications were 
associated with the procedure and 24 h after the injection the carpal hyperflexion resolved.
Relevance and novel information The use of BTX-A to treat muscle contractures in human medicine is an established 
and increasingly used technique. For example, in subacute stroke patients with a non-functional arm, BTX-A forearm 
injection appears to prevent disabling finger stiffness, likely by minimising the development of contractures. Here, 
we demonstrate that intramuscular BTX-A is an effective treatment for acquired muscle contractures in a cat.
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treatments with a higher degree of morbidity and/or 
recurrence, such as tenectomy, myectomy, arthrodesis 
and amputation.4 There is therefore a demand for 
lower-risk treatments for severe muscle contracture in 
veterinary patients.
Clostridium botulinum produces seven serotypes of 
the neurotoxin: botulinum toxin (BTX) type A–G. These 
toxins inhibit acetylcholine exocytosis at the synaptic 
cleft in cholinergic nerve terminals preventing muscle 
contraction.5 However, there are some variations in 
their potency, duration of action and intracellular pro-
tein targets. BTX-A reduces muscular activity in a dose-
dependent manner, making it safe and predictable for 
therapeutic use.6,7
In this case report we describe the first successful use 
of intramuscular BTX-A to treat severe muscle contrac-
tures in a cat, where the alternative treatment option 
was amputation.
Case description
A 4-month-old male entire indoor-only domestic 
shorthair cat was referred to the Royal (Dick) School 
of Veterinary Studies’ Neurology Service for acute 
onset of right thoracic monoparesis following a fall 
from a chair. Clinical signs progressed rapidly and 
within 18 h the cat was unable to walk, with right 
hemiplegia, left hemiparesis and right Horner’s syn-
drome. At this stage the patient was referred. 
On presentation the cat was quiet, alert and respon-
sive; vitals were within normal limits; and a large, 
firm bladder was evident on abdominal palpation. 
Neurological examination revealed anisocoria with a 
miotic right pupil, cervical hyperaesthesia, right hemi-
plegia, left hemiparesis, thoracic limb hypotonia, pel-
vic limb hypertonia, right thoracic limb areflexia, 
absent deep pain in the right thoracic limb below the 
elbow and pelvic limb hyperreflexia. Neurolocalisation 
was to the C6–T2 spinal segments, with lateralisation 
to the right. Differential diagnoses were trauma, vas-
cular event and infectious/inflammatory disease 
(feline infectious peritonitis/toxoplasmosis).
An emergency CT scan (64-row multi-slice CT scan-
ner; Somatom Definition AS) of the head and spine was 
performed shortly after admission; no structural abnor-
malities were identified to explain the clinical signs. 
Serum biochemistry and haematology identified no sig-
nificant findings. An echocardiogram revealed trivial tri-
cuspid regurgitation, no left atrial enlargement, no 
thrombus formation and good contractility. Activated 
partial thromboplastin time (APTT) and prothrombin 
time (PT) were within their respective reference intervals 
(RIs), and serum fibrinogen concentration was not 
increased: APTT 13.4 s (RI 10–20 s); PT 10.2 s (RI 5–12 s); 
and fibrinogen 3.2 g/l (RI 2–4 g/l). Testing for serum 
feline leukaemia virus antigen and feline 
immunodeficiency virus antibody was negative (SNAP 
FIV/FeLV Combo Test; IDEXX). Serum IgG and IgM 
antibody titre testing for Toxoplasma gondii was negative 
(<50 [Biobest Laboratories, Edinburgh]). Serum analysis 
for feline coronavirus antibody titre by immunofluores-
cence assay (<10) and alpha1-acid glycoprotein by radial 
immunodiffusion assay (0.5 g/l; RI 0.124–0.878 g/l) were 
both negative (Biobest Laboratories). Analysis of the cer-
ebrospinal fluid (CSF) showed a total cell count of 39.6/
µl (RI <5/µl) and a total protein concentration of 1.28 g/l 
(RI <0.45 g/l). Cytology of the CSF fluid revealed 
increased red blood cells (RBCs) and scattered platelets. 
The nucleated cells were approximately 8/1000 RBCs 
and they comprised 30% non-degenerate neutrophils, 46% 
small and a few medium lymphocytes, 23% large mononu-
clear cells (monocytes and macrophages) and 1% eosino-
phils. One macrophage showed erythro phagocytosis; 
otherwise, cell morphology was unremarkable. No aetio-
logical agents were seen. These findings were consistent 
with either local haemorrhage or blood contamination.
Based on history, neurological examination and inves-
tigations, a presumptive diagnosis of spinal cord trauma 
was made. Daily physiotherapy was initiated included 
passive range of motion (PROM) exercises. The patient 
was managed symptomatically with buprenorphine 
(20 μg/kg IV q8h), dexamethasone (0.1 mg/kg IV q24h, 
increased to 0.2 mg/kg on result of negative T gondii), 
clindamycin (25 mg/kg PO q8h, withdrawn on result of 
negative toxoplasma), ranitidine (2 mg/kg IV q12h) and 
prazocin (250 μg/kg PO q8h) to aid frequent bladder 
expressions. Lactulose and enemas containing sodium 
citrate (450 mg) and sodium alkylsulfoacetate (45 mg 
[Micralax; RPH Pharmaceuticals]) were used to manage 
faecal retention. 
Seven days after the initial trauma the patient failed 
to show significant signs of improvement and appeared 
to have persistent cervical hyperaesthesia, despite anal-
gesia and physiotherapy. Pre- and post-contrast MRI 
(3Philips Intera 1.5-T Pulsar System; Philips Medical 
Systems) study of the cervical and thoracic spine and 
brain was performed. All visible intervertebral discs 
showed normal T2 fluid intensity (Figure 1a). At C6–C7 
the intervertebral disc was protruding into the mid-ven-
tral vertebral canal, causing thinning of the subarach-
noid space circumferentially and mild dorsal cord 
deviation (Figure 1b,c). Extending from C5–C6 to cranial 
C7, the spinal cord contained a large area of T1, T2 and 
T2* hyperintensity, with only the left dorsolateral aspect 
of the cord unaffected. In the same area, there was 
marked contrast enhancement of the right lateral aspect 
of the spinal cord (Figure 1d). MRI findings were there-
fore consistent with a C6–C7 acute non-compressive 
nucleus pulposus extrusion with secondary C5–C7 spi-
nal cord chronic haemorrhage. The contrast enhance-
ment was considered to be most likely due to vascular 
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damage, inflammation secondary to the trauma and 
chronic haemorrhage. CSF analysis was repeated 7 days 
post-trauma and was consistent with normal CSF: total 
cell count 0 (RI <5/µl) and total protein concentration 
0.35 g/l (RI <0.45 g/l), suggesting resolution of the 
previously suspected subarachnoid haemorrhage.
Following MRI, a splint was applied to the right tho-
racic limb to prevent knuckling and abrasion of the dor-
sal paw, and to assist ambulation. By 10 days post-trauma 
the anisocoria, cervical hyperaesthesia, left-sided paresis 
and postural deficits, pelvic limb hypertonus, and 
faecal and urinary retention had resolved. The 
kitten was able to run, jump and climb. However, the 
distal right thoracic limb was still paralysed, and 
over the preceding 10 days progressive contracture of 
the right carpus developed. PROM exercises elicited 
pain on extension of the carpus and flexion of the 
elbow, preventing the physiotherapy from being per-
formed effectively. Splints were trialled, but they also 
elicited discomfort. Radiographs of the thoracic limbs 
were taken. No soft tissue abnormalities were detected. 
An 18° lateral deviation of the right carpus was evident, 
causing narrowing of the radiocarpal joint space affect-
ing primarily the intermedioradial carpal bone. This 
was consistent with suspected contracture of the triceps 
and flexor muscles of the carpus and digits.
The contracture resulted in the development of a 
non-weightbearing carpal hyperflexion (Figure 2). 
Amputation of the limb or a therapeutic trial with BTX 
were discussed; the owners elected for the latter. Under 
general anaesthesia, 90 units of BTX type A (BTX-A 
[Botox Cosmetic; Allergan]) were injected into the 
flexor muscles of carpus and digits, and 10 units into 
the triceps. The dose was similar to what has previ-
ously been shown to be safe in cats in an experimental 
study.8 The aim of the treatment was to alleviate dis-
comfort and reduce the muscle spasticity, allowing 
the use of a brace and physiotherapy to be performed. 
Figure 1 MRI study of the cervical spine. (a) T2-weighted (T2W) sagittal image demonstrates that all visible intervertebral discs 
have normal T2 fluid intensity and a T2 hyperintensity extending from C5–C6 to cranial C7. (b) T2W and (c) T1-weighted (T1W) 
transverse images demonstrate the C6–C7 intervertebral disc protruding into the mid-ventral vertebral canal, causing thinning 
of the subarachnoid space circumferentially and mild dorsal spinal cord deviation. (d) T1W transverse image post-contrast 
demonstrates marked contrast enhancement of the right lateral aspect of the spinal cord in the area of T2 hyperintensity
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The patient was monitored in hospital for 48 h after the 
treatment; there were no adverse clinical reactions. The 
cat was discharged with a splint to aid ambulation; the 
owners were instructed to change the splint daily and 
perform daily physiotherapy.
At a re-check 8 days post-BTX-A treatment the own-
ers perceived the cat to be pain-free and ambulating well 
with support from the splint. The owners were manag-
ing well with the daily splint changes and rehabilitation 
exercises, although they reported that the cat resented 
the removal of the tape that kept the splint in place. 
Examination showed erythema where the tape was 
applied. The tape was replaced with a custom-made 
brace made with a spoon splint and Velcro straps. Repeat 
neurological examination showed that in the right tho-
racic limb postural reactions were still absent, sensation 
was decreased but now present at the second and fifth 
digit, and the muscle contractions had resolved but mus-
cle tone was decreased. The postural reactions and tone 
in the other limbs were now normal. Mild hyperaesthe-
sia of the cervical, epaxial and shoulder muscles was 
present, but there was a greatly improved level of com-
fort on manipulation of neck, right shoulder, elbow and 
carpus vs before BTX-A treatment. The owners reported 
that the cat was very active; we suspected that the neck 
and shoulder muscles were subjected to an increased 
load secondary to the reduced tone and function of the 
injected muscles of the right thoracic limb.
The cat continued to make a clinical improvement. At 
6 months post-BTX-A treatment, sensation was present 
but still decreased on the distal right thoracic limb. The 
right triceps brachii muscle was atrophied and a mild 
increase in muscle tone had returned. However, normal 
mobility was not impeded and the cat was pain free and 
able to place its right thoracic paw in a normal position 
when ambulating, only requiring support from the 
splint after prolonged periods of exercise (see the video 
in the supplementary material). The residual clinical 
signs did not appear to be affecting its quality of life.
Discussion
The first published report documenting the therapeutic 
use of BTX-A was in 1981, to treat strabismus in human 
patients.9 Since then, the use of BTX-A as a therapeutic 
agent in human medicine has grown dramatically and 
has been shown to successfully treat a range of diseases. 
Most relevant to this case report, BTX-A is now a rela-
tively well-established technique to treat spasticity and 
contracture in human medicine. For example, in sub-
acute human stroke patients, early intramuscular BTX-A 
injection has been shown to prevent the development of 
disabling finger flexor stiffness over a 6-month period, 
most likely by attenuating the development of muscle 
contractures.10 Furthermore, in children with cerebral 
palsy, BTX-A injections into spastic or dystonic muscles 
have been shown to reduce pain and deformity and 
decrease the need for surgical intervention.11
The therapeutic use of BTX-A in veterinary medi-
cine is less well documented, with limited literature. A 
randomised, double-blind, placebo-controlled clinical 
trial by Heikkilä et al demonstrated that intra-articular 
injection of BTX-A may reduce pain in dogs with 
chronic osteoarthritis.12 However, these results were 
unrepeatable in a recent and similarly designed study.13 
Injection of BTX-A into the muscularis layer of the 
pylorus has been shown to improve gastric emptying 
in a Toy Australian Shepherd dog with a functional 
pyloric outflow obstruction that was refractory to 
prokinetic therapy.14 Furthermore, radiation therapy-
induced myokymia and neuromyotonia in a Maltese 
was well controlled with BTX-A injections into the 
affected muscles.15 Most comparable to this case report, 
Bright et  al describe a case where an 11-week-old 
domestic shorthair cat presented with tarsal arthro-
gryposis and 20 U of BTX-A was injected into the gas-
trocnemius.16 However, 14 days later there was 
minimal improvement in range of motion (~5°) and 
partial tarsal arthrodesis and calcaneal tendon length-
ening was subsequently performed. Two factors may 
have contributed to the failure of treatment in this pre-
vious case report. First, a lower dose of BTX-A was 
used when compared with this current case (20 U vs 
Figure 2 Photograph demonstrating non-weightbearing 
carpal hyperflexion, secondary to severe muscle contracture
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100 U). Second, this was a congenital contracture in 
contrast to an acquired contracture and therefore the 
pathology contributing to the contracture would likely 
be more permanent. To our knowledge, this case report 
describes the first successful use of BTX-A to treat 
muscle contracture in the veterinary literature.
The success of BTX-A treatment in human patients is 
dependent on the adjunctive use of regular physiother-
apy and splinting or casting.17 Assuming that the same 
would be true for veterinary patients, case selection is 
important as a significant investment of time and money 
is required from the owner. The only complication fol-
lowing treatment in the current case was erythema and 
discomfort caused by the tape that held the splint in 
place, which quickly resolved following the replacement 
of the tape with Velcro straps.
Conclusions
Here we demonstrate, for the first time, that intramuscular 
BTX-A is an effective and safe treatment for acquired muscle 
contractures in a juvenile cat. The goal of BTX-A treatment 
should be to maintain a pain-free and functional limb, and 
where that fails, surgical intervention would likely be the 
treatment of choice. Based on the results of this case report, 
and the established and growing use in human medicine, 
we believe that the use of BTX-A to treat muscle contracture 
in the veterinary field warrants further investigations.
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